Table 1.
Baseline Demographics and Disease Characteristics
| Total Study Cohort(n = 71) | Subset of Subjects with Pretreatment Tissue Biopsies(n = 47) | Remaining Subjects(n = 24) | P-value | |
|---|---|---|---|---|
| Age (years) | 0.9466 | |||
| Mean (SD) | 62.54 (10.0) | 62.43 (9.2) | 62.75 (11.6) | |
| Median | 62 | 62 | 61.5 | |
| Age, n(%) | 0.8108 | |||
| < 70 | 52 (73) | 34 (72) | 18 (75) | |
| > = 70 | 19 (27) | 13 (28) | 6 (25) | |
| Sex, n(%) | 0.5282 | |||
| Female | 26 (37) | 16 (34) | 10 (42) | |
| Male | 45 (63) | 31 (66) | 14 (58) | |
| ECOG Status, n(%) | 0.1672 | |||
| 0 | 22 (31) | 17 (36) | 5 (21) | |
| 1 | 44 (62) | 28 (60) | 16 (67) | |
| 2 | 3 (4) | 2 (4) | 1 (4) | |
| 3 | 2 (3) | – | 2 (8) | |
| Stage, n(%) | 0.3136 | |||
| IIIA | 4 (6) | 2 (4) | 2 (8) | |
| IIIB | 8 (11) | 7 (15) | 1 (4) | |
| IV | 59 (83) | 38 (81) | 21 (88) | |
| Histology, n(%) | 0.4137 | |||
| Adenocarcinoma | 68 (96) | 45 (96) | 23 (96) | |
| Adenocarcinoma|Large cell carcinomaa | 1 (1) | – | 1 (4) | |
| Adenocarcinoma|Squamous cell carcinomaa | 2 (3) | 2 (4) | – | |
| 1 L Therapy Received, n(%) | 0.8582 | |||
| Chemotherapy Onlyb | 31 (44) | 21 (45) | 10 (42) | |
| Chemo+Radiationc | 25 (35) | 17 (36) | 8 (33) | |
| Chemo+Targetedd | 9 (13) | 6 (13) | 3 (13) | |
| Chemo+Radiation+Targetedd | 6 (8) | 3 (6) | 3 (13) | |
| Smoking Status, n(%) | 0.8495 | |||
| Never Smoker | 11 (15) | 6 (13) | 5 (21) | |
| Quit more than 5 years ago | 9 (13) | 6 (13) | 3 (13) | |
| Quit less than 5 years ago | 9 (13) | 6 (13) | 3 (13) | |
| Current Smoker | 42 (59) | 29 (62) | 13 (54) |
ECOG, Eastern Cooperative Oncology Group; SD, standard deviation. aAll subjects received an initial diagnosis of adenocarcinoma; however, additional histology was reported after re-biopsy; bCisplatin/carboplatin plus pemetrexed; cRadiation included for brain or bone metastatic sites; dTargeted therapy was bevacizumab in 13 subjects, erlotinib plus chemotherapy and radiation in 1 subject, and 1 subject received Nivolumab after chemotherapy and bevacizumab